A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients

DOI10.1080/01621459.2013.806927MaRDI QIDQ2861803zbMATH OpenOpenAlexWikidataFDO

Authors Thomas M. Braun, Jin Zhang

Publication date 11 November 2013

Published in Journal of the American Statistical Association (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc3821780

zbMATH Keywords

Bayesian statisticsclinical trialdynamic treatment regimedose-escalation studynonmixture cure model

Mathematics Subject Classification ID

Statistics (62-XX)

Cites work

• A nonidentifiability aspect of the problem of competing risks.
• AMCMC: an R interface for adaptive MCMC
• Analysis of multivariate survival data
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
• Optimal Dynamic Treatment Regimes
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Cited in

(6)

• Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
• Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
• A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
• Adaptive clinical trial designs for phase I cancer studies

This page was built for publication: A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2861803)